[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334393-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334393-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lessons-learned-from-20-years-of-preclinical-testing-in-pediatric-cancers","Lessons learned from 20 years of preclinical testing in pediatric cancers","","Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute since 2004 to collaborate with industry partners and address the limited availability of targeted agents for pediatric cancers. Distinct pediatric tumor biology and small patient populations complicate oncology drug development, intensified by genomic subclassification. The imbalance between many candidate agents and few patients requires careful prioritization of adult-developed agents for pediatric trials, with over 100 efficacy-testing results summarized to guide candidate selection. The review consolidates lessons from two decades of preclinical trial design and execution using antineoplastic agents in murine childhood cancer models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lessons-learned-from-20-years-of-preclinical-testing-in-pediatric-cancers/334393/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lessons-learned-from-20-years-of-preclinical-testing-in-pediatric-cancers/334393.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem did NCI-supported pediatric preclinical testing programs aim to address?","Question",{"text":63,"@type":64},"They aimed to help address the paucity of targeted agents for pediatric cancers compared with the much larger number developed for adult malignancies, by enabling collaborative preclinical efficacy testing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is pediatric cancer drug development particularly challenging?",{"text":68,"@type":64},"Distinct pediatric tumor biology, small numbers of pediatric patients, and extensive genomic sub-classification create major constraints on selecting and evaluating therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"How do researchers choose among many candidate agents despite limited pediatric patients?",{"text":72,"@type":64},"The programs require careful prioritization of adult-developed candidate agents for clinical evaluation in children with cancer, informed by published efficacy-testing results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334393,1790467414,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Pharmacol Ther. Author manuscript; available in PMC 2025 May 18. |\n| --- | --- |\n\nPublished in final edited form as:  \nPharmacol Ther. 2024 December ; 264: 108742. doi:10.1016/j.pharmthera.2024.108742 .  \nLessons learned from 20 years of preclinical testing in pediatric cancers  \nMalcolm A. Smitha,* , Peter J. Houghtonb, Richard B. Lockc, John M. Marisd, Richard Gorlicke, Raushan T. Kurmashevab, Xiao-Nan Lif, Beverly A. Teichera, Jeffrey H. Chuangg, Filemon S. Dela Cruzh, Michael A. Dyeri, Andrew L. Kungh, Michael W. Lloydj, Yael P. Mosséd, Timothy M. Stearnsj, Elizabeth A. Stewart i, Carol J. Bultj, Stephen W. Ericksonka National Cancer Institute, Bethesda, MD, United States of America  \nbThe University of Texas Health at San Antonio, TX, United States of America  \ncChildren’s Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia  \ndThe Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America  \neThe University of Texas MD Anderson Cancer Center, Houston, TX, United States of America fLurie Children’s Hospital, Northwestern University Feiberg School of Medicine, Chicago, IL, United States of America  \ngThe Jackson Laboratory for Genomic Medicine, Farmington, CT, United States of America hMemorial Sloan Kettering Cancer Center, New York City, NY, United States of America  \niSt. Jude Children’s Research Hospital, Memphis, TN, United States of America  \njThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, United States of America kRTI International, Research Triangle Park, NC, United States of America  \nThis is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \n*Corresponding author at: National Cancer Institute, 9609 Medical Center Drive, RM 5-W414, MSC 9737, Bethesda, MD 20892, [United States of America. Malcolm.Smith@nih.gov](United States of America. Malcolm.Smith@nih.gov) (M.A. Smith).  \nDeclaration of competing interest  \nThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.  \nCRediT authorship contribution statement  \nMalcolm A. Smith: Writing – review & editing, Writing – original draft, Conceptualization. Peter J. Houghton: Writing – review & editing, Writing – original draft, Conceptualization. Richard B. Lock: Writing – review & editing, Writing – original draft, Conceptualization. John M. Maris: Writing – review & editing, Writing – original draft, Conceptualization. Richard Gorlick:  \nWriting – review & editing, Writing – original draft, Conceptualization. Raushan T. Kurmasheva: Writing – review & editing, Writing – original draft, Conceptualization. Xiao-Nan Li: Writing – review & editing. Beverly A. Teicher: Writing – review & editing, Writing – original draft. Jeffrey H. Chuang: Writing – review & editing. Filemon S. Dela Cruz: Writing – review & editing. Michael A. Dyer: Writing – review & editing. Andrew L. Kung: Writing – review & editing. Michael W. Lloyd: Writing – review & editing, Writing – original draft. Yael P. Mossé: Writing – review & editing, Writing – original draft. Timothy M. Stearns:  \nWriting – review & editing. Elizabeth A. Stewart: Writing – review & editing, Writing – original draft. Carol J. Bult: Writing – review & editing, Project administration. Stephen W. Erickson: Writing – review & editing, Writing – original draft, Methodology, Conceptualization.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nSmith et al. Page 2  \nAbstract  \nPrograms for preclinical testing of targeted cancer agents in murine models of ","cbCaismZA8J5b8Jm","https://ap.wps.com/l/cbCaismZA8J5b8Jm","pdf",1039896,68,"English","# Abstract\n# Introduction","[{\"question\":\"What problem did NCI-supported pediatric preclinical testing programs aim to address?\",\"answer\":\"They aimed to help address the paucity of targeted agents for pediatric cancers compared with the much larger number developed for adult malignancies, by enabling collaborative preclinical efficacy testing.\"},{\"question\":\"Why is pediatric cancer drug development particularly challenging?\",\"answer\":\"Distinct pediatric tumor biology, small numbers of pediatric patients, and extensive genomic sub-classification create major constraints on selecting and evaluating therapies.\"},{\"question\":\"How do researchers choose among many candidate agents despite limited pediatric patients?\",\"answer\":\"The programs require careful prioritization of adult-developed candidate agents for clinical evaluation in children with cancer, informed by published efficacy-testing results.\"}]","Lessons learned from 20 years of preclinical testing in pediatric cancers | PDF",1790006493,171]